ILMN vs. NTRA: Illumina vs. Natera Stock Comparison
How do Illumina (ILMN) and Natera (NTRA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Illumina (ILMN) and Natera (NTRA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while NTRA is classified in Biotechnology.
| Profile Item | ILMN | NTRA |
|---|---|---|
| Name | Illumina Inc. | Natera, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 32.23 billion USD | 45.05 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 28, 2000 | July 1, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| Total Return (1Y) | 79.70% | 61.03% |
| Total Return (3Y, Annualized) | 28.16% | 92.02% |
| Total Return (5Y, Annualized) | -10.65% | 23.20% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| Volatility (1Y, Annualized) | 48.47% | 52.30% |
| Beta (5Y) | 1.46 | 1.58 |
| Max Drawdown (5Y) | -82.95% | -75.72% |
| Avg. Volume (3M) | 2.77M | 1.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| Sharpe Ratio (1Y) | 1.56 | 1.09 |
| Sortino Ratio (1Y) | 2.25 | 1.63 |
Profitability
ROE (TTM)
Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.39%
- Max
- 109.18%
- ILMN
- 32.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.72%
- ILMN
- 19.72%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Illumina (ILMN) reports 20.02%, ranking against industry peers normally.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 83.12%
- ILMN
- 20.02%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| ROE (TTM) | 32.39% | -10.55% |
| ROA (TTM) | 8.32% | -6.79% |
| Net Margin (TTM) | 19.72% | -5.66% |
| Operating Margin (TTM) | 20.02% | -7.64% |
| Gross Margin (TTM) | 67.68% | 65.14% |
Growth
Revenue Growth
Natera (NTRA) at 35.90% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neither Illumina (ILMN) nor Natera (NTRA) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| Revenue Growth (YoY) | -0.66% | 35.90% |
| Revenue Growth (3Y CAGR) | -1.78% | 41.14% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Illumina (ILMN) at 2.63 and Natera (NTRA) at 2.81 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ILMN
- 2.63
- Q1
- 2.47
- Min
- 0.10
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Natera (NTRA) at 0.13 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.74
- Max
- 1.42
- ILMN
- 0.74
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| Current Ratio (MRQ) | 2.63 | 2.81 |
| Debt / Equity (MRQ) | 0.74 | 0.13 |
| Net Debt / EBITDA | 0.85 | -- |
Dividends
Dividend Yield (TTM)
Neither Illumina (ILMN) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Illumina (ILMN) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.68
- Max
- 85.34
- Q3
- 43.46
- ILMN
- 36.68
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
P/S Ratio (TTM)
On P/S ratio, both Illumina (ILMN) at 7.10 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.10
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ILMN
- 7.10
- Q1
- 3.01
- Min
- 0.01
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Natera (NTRA) at 23.99 prices even higher, above its industry range.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.30
- Max
- 13.53
- ILMN
- 10.30
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ILMN | NTRA |
|---|---|---|
| P/E Ratio (TTM) | 36.68 | -- |
| P/S Ratio (TTM) | 7.10 | 15.49 |
| P/B Ratio (MRQ) | 10.30 | 23.99 |
| Free Cash Flow Yield (TTM) | 2.67% | 0.19% |